Invirum (Aciclovir)

Aciclovir is taken up preferentially by virus‑infected cells, where viral thymidine kinase converts it to aciclovir monophosphate. Subsequent cellular kinases produce the active triphosphate, which competitively inhibits viral DNA polymerase, blocking viral DNA synthesis while sparing normal host cells.

The dose of Invirum is determined by the prescribing clinician based on the specific infection, patient age, renal function, and other clinical factors. Healthcare professionals adjust the regimen to achieve optimal antiviral effect while minimizing risk.

Data on aciclovir use in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under medical supervision.

To order Invirum, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Invirum (aciclovir) is a first‑generation antiviral with a well‑established safety profile. Compared with newer agents such as valacyclovir or famciclovir, aciclovir may require more frequent dosing but is effective for the same herpesvirus infections and is often less expensive.

Invirum should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct heat, and ensure the container is tightly closed to maintain stability.

Invirum is administered orally. The tablets (or oral formulation) should be swallowed whole with a glass of water and can be taken with or without food, unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, include acute renal impairment, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, bone‑marrow suppression, seizures, and hepatitis. Patients should seek immediate medical attention if any of these occur.

Invirum should be avoided in individuals with known hypersensitivity to aciclovir or any component of the formulation. Patients with severe renal impairment may require dose adjustment or alternative therapy, and those with a history of serious allergic reactions should consult a physician before use.